UK's Sareum posts half-year loss as R&D spending continues

Sareum Holdings

12/03/2026 07:13

Overview

UK biotech firm reported half-year loss as R&D spending continued on autoimmune and cancer pipeline

Company restarted Phase 2-enabling toxicology for SDC-1801 after confirming earlier safety findings were unrelated

Cash at 31 Dec 2025 was £2.5 mln, with ongoing activities funded from existing resources

Outlook

Company expects dosing phase of SDC-1801 toxicology programme to complete in mid-2026

Sareum anticipates full Phase 2-enabling regulatory package for SDC-1801 by year-end

Company plans to advance portfolio through targeted business development and partnerships

Result Drivers

FORMULATION AND CMC DEVELOPMENT - Ongoing work to optimise SDC-1801 formulation and manufacturing contributed to R&D spend

NEUROSCIENCE COLLABORATION - Continued investment in TYK2 neuroscience discovery programme with Receptor.AI added to period costs

Company press release: ID:nRSL3116Wa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 EPS
-GBP 0.01
H1 EBIT
-GBP 1.82 mln
H1 Pretax Profit
-GBP 1.85 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)